Sacituzumab and zimberelimab for lung cancer after surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs (sacituzumab and zimberelimab) for people with non-small cell lung cancer that was confined to the chest, was surgically removed, but not completely cleared by prior chemotherapy and immunotherapy. The goal is to see if this treatment can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with non-small cell lung cancer (the most common type of lung cancer).
- You had surgery to remove the entire tumor (called R0 resection), like a lobectomy or pneumonectomy.
- You received chemotherapy plus immunotherapy (a PD-1 inhibitor) before surgery.
- After that pre-surgery treatment, some cancer still remained in the removed tissue (no complete response).
- Your cancer stage after surgery is IB, IIA, IIB, IIIA, or IIIB (with N2 lymph node involvement).
- You are in generally good health (ECOG 0-1) and at least 18 years old.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a new drug (sacituzumab tirumotecan) to pembrolizumab for people with non-small cell lung cancer that did not completely disappear after initial treatment and surgery. The goal is to see if the combination works better than pembrolizumab alone.
This trial tests a combination of two drugs — a targeted chemotherapy and an immunotherapy — given before surgery for people with early-stage but locally advanced lung cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests a combination of two drugs (sacituzumab tirumotecan and tagitanlimab) given before surgery for people with a specific type of lung cancer that is PD-L1 positive and can be removed. The goal is to see if this treatment helps shrink the tumor and improves outcomes after surgery.
This study tests a combination of two drugs for stage III lung cancer that can't be removed by surgery. One drug is an antibody-drug conjugate that targets cancer cells, and the other is an immunotherapy that helps your immune system fight cancer. The goal is to see if this combo shrinks or controls the tumor.
This trial tests two drugs, sacituzumab tirumotecan and limertinib, given before surgery to people with stage 3 non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination can shrink the tumor enough to allow surgery.
This trial tests whether giving two immunotherapy drugs before surgery can help shrink non-small cell lung cancer and improve treatment success. The drugs are toripalimab and sacituzumab tirumotecan, which are given as intravenous infusions.
Hear when a new Lung Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.